DMIIDrugs Made In America Acquisition II Corp.

1. Apr 28, 2026As previously disclosed, on November 17, 2025, Drugs Made in America Acquisition II Corp. (the “Company”) appointed Saleem Elmasri as Chief Financial Officer of the Company and entered into a Master Services Agreement (the “Consulting Agreement”) with Titan Advisory Services LLC for the provision of such principal …Material agreement entered · Form 8-K
2. Apr 3, 2026As previously disclosed, on March 11, 2026, Drugs Made In America Acquisition II Corp. (the “Company”) issued an unsecured convertible note (the “Bridge Note”) to Alpha Multi Family Office (the “Investor”) in the principal amount of $150,000 (the “Bridge Loan”)Material agreement entered · Form 8-K
3. Mar 17, 2026On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “Company”) issued an unsecured convertible note (the “Bridge Note”) to Alpha Multi Family Office (the “Investor”) in the principal amount of $150,000 (the “Bridge Loan”)Material agreement entered · Form 8-K
4. Mar 6, 2026As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026, Drugs Made In America Acquisition II Corp. (the “Company”) announced that, between the completion of its initial public offering on September 26, 2025 and December 31, 2025, the sponsor to the …Other event · Form 8-K
5. Mar 6, 2026As previously reported in the Quarterly Report on Form 10-Q for the period ended September 30, 2025, for Drugs Made In America Acquisition II Corp. (the “Company”), between the completion of the Company’s initial public offering on September 26, 2025 and September 30, 2025, the sponsor to the Company (the “Sponsor”) …Director or officer change · Form 8-K
6. Nov 18, 2025Resignation of Principal Financial and Accounting Officer On October 8, 2025, Glenn Worman, the Chief Financial Officer and principal financial and accounting officer of Drugs Made In America Acquisition II Corp. (the “Company”) delivered to the Company a notice of resignation from his position as Chief Financial …Director or officer change · Form 8-K
7. Oct 2, 2025As previously disclosed on a Current Report on Form 8-K dated September 24, 2025, Drugs Made In America Acquisition II Corp. (the “Company”) consummated its initial public offering (the “IPO”) of 50,000,000 units (the “Units”)Other event · Form 8-K
8. Sep 29, 2025On September 24, 2025, the registration statement (File No. 333-288791) (as amended, the “Registration Statement”) relating to the initial public offering (“IPO”) of Drugs Made In America Acquisition II Corp. (the “Company”) was declared effective by the Securities and Exchange Commission (the “Commission”)Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.